BACKGROUND: There is increasing evidence that the presence of an ongoing systemic inflammatory response is associated with poor outcome in patients with advanced cancer. The aim of this study was to validate whether an inflammation-based prognostic score (Glasgow Prognostic Score, GPS) is associated with survival in patients with advanced stage (stage III/IV) ovarian cancer. PATIENTS AND METHODS: An audit was conducted of patients with a new diagnosis of stage III or IV ovarian cancer presenting to the West London Gynae-Oncology Centre between October 2003 and June 2006 (n=154). The GPS was constructed as follows: Patients with both an elevated C-reactive protein (>10 mg/l) and hypoalbuminaemia (<35 g/l) were allocated a score of 2. Patients in whom only one or none of these biochemical abnormalities was present were allocated a score of 1 or 0, respectively. RESULTS: On univariate analysis GPS, histological type, ALP, performance status, primary surgery and ascites were predictors of overall survival. On multivariate a high GPS score, non-serous histology, high ALP and no initial surgery were independent predictors of worse overall survival in this population. CONCLUSIONS: The presence of a systemic inflammatory response, as measured by the GPS, is an independent predictor of poor overall survival in patients with advanced ovarian cancer independent of treatment received.
BACKGROUND: There is increasing evidence that the presence of an ongoing systemic inflammatory response is associated with poor outcome in patients with advanced cancer. The aim of this study was to validate whether an inflammation-based prognostic score (Glasgow Prognostic Score, GPS) is associated with survival in patients with advanced stage (stage III/IV) ovarian cancer. PATIENTS AND METHODS: An audit was conducted of patients with a new diagnosis of stage III or IV ovarian cancer presenting to the West London Gynae-Oncology Centre between October 2003 and June 2006 (n=154). The GPS was constructed as follows: Patients with both an elevated C-reactive protein (>10 mg/l) and hypoalbuminaemia (<35 g/l) were allocated a score of 2. Patients in whom only one or none of these biochemical abnormalities was present were allocated a score of 1 or 0, respectively. RESULTS: On univariate analysis GPS, histological type, ALP, performance status, primary surgery and ascites were predictors of overall survival. On multivariate a high GPS score, non-serous histology, high ALP and no initial surgery were independent predictors of worse overall survival in this population. CONCLUSIONS: The presence of a systemic inflammatory response, as measured by the GPS, is an independent predictor of poor overall survival in patients with advanced ovarian cancer independent of treatment received.
Authors: Sebastian Trousil; Patrizia Lee; Robert J Edwards; Lynn Maslen; Jingky P Lozan-Kuehne; Ramya Ramaswami; Eric O Aboagye; Stephen Clarke; Christopher Liddle; Rohini Sharma Journal: Br J Pharmacol Date: 2019-08-05 Impact factor: 8.739
Authors: Cindy S Y Tan; Jane A Read; Viet H Phan; Philip J Beale; Jennifer K Peat; Stephen J Clarke Journal: Support Care Cancer Date: 2014-08-13 Impact factor: 3.603
Authors: Helena Sheikhet Migalovich; Vyacheslav Kalchenko; Nava Nevo; Gila Meir; Fortune Kohen; Michal Neeman Journal: Cancer Res Date: 2009-06-09 Impact factor: 12.701
Authors: Katy Milne; Cheryl Alexander; John R Webb; Winnie Sun; Kristy Dillon; Steve E Kalloger; C Blake Gilks; Blaise Clarke; Martin Köbel; Brad H Nelson Journal: J Transl Med Date: 2012-02-27 Impact factor: 5.531
Authors: Matthew S Block; Bridget Charbonneau; Robert A Vierkant; Zachary Fogarty; William R Bamlet; Paul D P Pharoah; Mary Anne Rossing; Daniel Cramer; Celeste Leigh Pearce; Joellen Schildkraut; Usha Menon; Susanne K Kjaer; Douglas A Levine; Jacek Gronwald; Hoda Anton Culver; Alice S Whittemore; Beth Y Karlan; Diether Lambrechts; Nicolas Wentzensen; Jolanta Kupryjanczyk; Jenny Chang-Claude; Elisa V Bandera; Estrid Hogdall; Florian Heitz; Stanley B Kaye; Peter A Fasching; Ian Campbell; Marc T Goodman; Tanja Pejovic; Yukie T Bean; Laura E Hays; Galina Lurie; Diana Eccles; Alexander Hein; Matthias W Beckmann; Arif B Ekici; James Paul; Robert Brown; James M Flanagan; Philipp Harter; Andreas du Bois; Ira Schwaab; Claus K Hogdall; Lene Lundvall; Sara H Olson; Irene Orlow; Lisa E Paddock; Anja Rudolph; Ursula Eilber; Agnieszka Dansonka-Mieszkowska; Iwona K Rzepecka; Izabela Ziolkowska-Seta; Louise A Brinton; Hannah Yang; Montserrat Garcia-Closas; Evelyn Despierre; Sandrina Lambrechts; Ignace Vergote; Christine S Walsh; Jenny Lester; Weiva Sieh; Valerie McGuire; Joseph H Rothstein; Argyrios Ziogas; Jan Lubiński; Cezary Cybulski; Janusz Menkiszak; Allan Jensen; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Andrew Berchuck; Anna H Wu; Malcolm C Pike; David Van Den Berg; Kathryn L Terry; Allison F Vitonis; Starr M Ramirez; David N Rider; Keith L Knutson; Thomas A Sellers; Catherine M Phelan; Jennifer A Doherty; Sharon E Johnatty; Anna deFazio; Honglin Song; Jonathan Tyrer; Kimberly R Kalli; Brooke L Fridley; Julie M Cunningham; Ellen L Goode Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-04-16 Impact factor: 4.254